Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02951156
Title Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer
Indications

diffuse large B-cell lymphoma

Therapies

Avelumab + Azacitidine + Utomilumab

Avelumab + Rituximab + Utomilumab

Bendamustine + Rituximab

Gemcitabine + Oxaliplatin + Rituximab

Avelumab + Bendamustine + Rituximab

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | BEL


No variant requirements are available.